The company invites investors, analysts and advisors to attend their interactive chat by the fire in real time
SOUTH EASTON, MA / ACCESSWIRE / January 19, 2022 / Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and “Company”), a leader in the development and sale of innovative, widely enabling and pressure-based instruments, consumables and services for food and beverage worldwide , the biotherapeutic and personal well-being industries, among others, announced today the company’s participation in the web seminar Innovations and Advances in the CBD Market on January 20, sponsored by FORCE Family Office. This real-time interactive “fire chat” will feature three companies that have launched or are about to launch important and innovative products and services and / or advances in the CBD space.
DATE: Thursday, January 20, 2022 (12:00 ET)
PRESENTATION: Video Webcast
REGISTRATION: Click here to register for the FORCE webinar
Panelists.
Pressure BioSciences, Inc. (OTCQB: PBIO) is planning to launch in mid-2022 its revolutionary Ultra Shear Technology ™ (UST ™) platform for the preparation of water-soluble, long-term stable, and highly bioavailable oil and water nanoemulsions (e.g., CBD oil and water ). Mr. Richard T. Schumacher, founder and CEO, will be a panel participant.
ProVerde Laboratories (Private) is a highly respected analytical testing laboratory that brings quality and integrity to the cannabis space. Dr. Christopher Hudalla, founder and CSO, was recently named one of the top 10 influencers in the science of cannabis. Dr. Hudalla will be a panel participant.
The Alkaline Water Company (NASDAQ: WTER) is a fast growing company that has recently launched an innovative CBD bottled water to offer functional benefits to consumers. Mr. Richard “Ricky” Wright, founder and CEO, will be a panel participant.
FORCE Family Office is the largest family office network in the United States. CEO Steven Saltzstein will be the moderator of the webinar.
The story goes on
Recently Selected Key Ads – PBIO
PBIO produces CBD oil nanoemulsions with a solid rock stability of 18 months
Plans for USM Demonstration and Toll Manufacturing Sites on US West and East Coasts Announced
Second US patent granted to the revolutionary UST platform
UST successfully transforms neem oil into a new and very powerful nanoemulsion for Agrochem use
UST Successfully nanoemulsified Astaxanthin: one of the most potent antioxidants in the world
PBIO has been awarded three international patents for its innovative UST platform
PBIO and Ohio State University announce the formation of the food industry consortium to advance the commercialization of the company’s UST technology platform
The PBIO aims at therapeutic efficacy with improved drug delivery and dosing safety through UST processing.
About FORCE Family Office
FORCE is the largest family office network in the United States with a significant and growing international presence. In 2020 alone, they hosted more than 160 events, a number they hope to surpass each year from now on. His team is dedicated to helping family offices connect successfully and effectively with private and public companies for co-investment, research, education and philanthropy.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, widely enabled and pressure-based solutions for the life sciences and other industries worldwide. Our products are based on the unique properties of constant (i.e., static) and alternating (i.e., pressure cycle or PCT) hydrostatic pressure technology. PCT is a patented technology platform that uses alternating hydrostatic pressure cycles between ambient levels and high altitudes to monitor biomolecular interactions in a safe and reproducible manner (e.g., cell lysis, biomolecule extraction). Our main focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutic characterization and quality control, soil and plant biology, forensics and bioterror applications. In addition, significant new market opportunities have arisen in the use of our pressure-based technologies in the following areas: (1) the use of our newly acquired patented technology from BaroFold, Inc. (“BaroFold” technology) to enable entry into the biopharmaceutical contract services industry, and (2) the use of our recently patented, scalable, high-efficiency Ultra Shear (“UST”) technology platform and pressure-based to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare stable, high-quality, homogenized liquid and low-acid foods that are stable at room temperature. of extended service life or which cannot be effectively preserved by existing non-thermal technologies.
Prospective statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve risks, uncertainties and other known and unknown factors that may substantially result in the actual results, activity levels, performance or achievements of our industry or industry. different from future results or levels. of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you may identify forward-looking statements by terminology such as “may”, “should”, “should”, “could”, “would be”, “wait”, “plan”, “intend”, “anticipate”. “” believes “,” estimates “,” predicts “,” projects “,” potential “or” continues “or the negative of these terms and other comparable terminology. These statements are only predictions based on our current expectations and projections of future events. You should not unduly trust these statements. When evaluating these statements, you should specifically consider several factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statements. risks, uncertainties and other factors include, but are not limited to, the risks and uncertainties addressed under “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 and other reports submitted. by the Time Company and I’m with the SEC. The company assumes no obligation to update any of the information included in this release, unless otherwise provided by law.
For more information on GDP and this press release, click on the following website link:
http://www.pressurebiosciences.com
Visit us on Facebook, LinkedIn and Twitter.
Press contacts:
Richard T. Schumacher, Chairman and Chief Executive Officer (508) 230-1828 (T)
Jeffrey N. Peterson, Chairman of the Board (650) 812-8121 (T)
SOURCE: Pressure BioSciences Inc.
View the source version on accesswire.com:
https://www.accesswire.com/684551/Pressure-BioSciences-to-Participate-in-FORCE-Family-Offices-January-20th-Webinar-Innovations-and-Advancements-in-the-46-Billion-CBD- Market
